Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHRENILIN vs BUTABARB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Tension headache
Sedative,Hypnotic,Anticonvulsant,Preoperative anxiety
For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
Butalbital: terminal half-life ~35 hours (range 20-50 h); acetaminophen: ~2-3 hours (prolonged in hepatic impairment); caffeine: ~3-6 hours.
Terminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
Butalbital is extensively metabolized by hepatic CYP450 enzymes (especially CYP2C9) and excreted in urine. Acetaminophen is primarily conjugated in the liver via glucuronidation and sulfation, with minor CYP2E1-mediated metabolism to a toxic metabolite (NAPQI). Caffeine is metabolized predominantly by CYP1A2.
Hepatic metabolism via CYP2C9 and CYP2C19; minor pathways involve glucuronidation.
PHRENILIN (butalbital/acetaminophen/caffeine): Renal excretion of metabolites; butalbital ~60-70% unchanged in urine, acetaminophen ~2-4% unchanged with majority as glucuronide and sulfate conjugates, caffeine metabolites primarily renal.
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
Butalbital: ~45% bound to plasma proteins; acetaminophen: 10-25% bound; caffeine: ~35% bound.
Approximately 20-25% bound to plasma proteins (albumin).
Butalbital: Vd ~0.8 L/kg; acetaminophen: Vd ~0.9 L/kg; caffeine: Vd ~0.6 L/kg. Overall Vd for combination not established; butalbital widely distributed.
0.5-0.6 L/kg in adults. Higher Vd suggests distribution into total body water and tissues; may increase in obesity.
Oral: butalbital ~90% (complete absorption); acetaminophen ~85-90%; caffeine ~100%.
Oral: 95-100% (well absorbed). Rectal: 80-90%. IM: 80-100%.
GFR 30-50 m L/min: Use with caution, maximum 4 capsules per day. GFR <30 m L/min: Avoid use due to accumulation of acetaminophen metabolites and butalbital. Not recommended in dialysis.
e GFR 30-50 m L/min: reduce dose by 25%. e GFR <30 m L/min: avoid use or use 50% reduction with caution.
Child-Pugh A: Use with caution, maximum 4 capsules per day. Child-Pugh B or C: Contraindicated due to impaired metabolism of butalbital and hepatotoxicity risk from acetaminophen.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Not recommended in children under 12 years of age due to butalbital and caffeine content. For adolescents 12-17 years: 1 capsule orally every 4 hours as needed, not exceeding 3 capsules per day.
0.5-1 mg/kg/dose orally every 6-8 hours; maximum 30 mg/dose. Not recommended for children under 6 years.
Initiate at 1 capsule orally every 4 hours as needed, not exceeding 4 capsules per day. Monitor for sedation, cognitive impairment, and falls. Avoid in patients with severe hepatic or renal impairment.
Initiate at 7.5-15 mg orally 2-3 times daily; increase slowly. Avoid in frail elderly. Monitor for paradoxical excitation.
Barbiturates (butalbital) are habit-forming and may produce drug dependence. Withdrawal symptoms (e.g., anxiety, insomnia, seizures) can occur if abruptly discontinued. Use with caution in patients with a history of substance abuse.
May be habit forming; potential for abuse and dependence. Abrupt discontinuation may precipitate life-threatening withdrawal symptoms.
Hepatotoxicity (acetaminophen) with overdose or chronic use; risk of dependence and withdrawal with butalbital; potential for caffeine-related effects (insomnia, palpitations); caution in patients with liver disease, renal impairment, or history of substance abuse.
Respiratory depression, especially when combined with other CNS depressants; tolerance and dependence; withdrawal seizures; use with caution in hepatic impairment and elderly.
Hypersensitivity to any component; porphyria (butalbital); severe hepatic impairment (acetaminophen); concurrent use of MAOIs or other CNS depressants may potentiate effects.
Hypersensitivity to barbiturates, porphyria, severe respiratory insufficiency, history of substance abuse.
Avoid or limit caffeine-containing foods and beverages (coffee, tea, cola, chocolate) due to additive caffeine content. Alcohol should be strictly avoided due to enhanced CNS depression and hepatotoxicity risk. Grapefruit juice may affect caffeine metabolism; monitor for increased caffeine effects.
Avoid grapefruit juice as it may inhibit metabolism and increase sedative effects. Take with food if gastrointestinal upset occurs. Limit caffeine intake as it may reduce sedative efficacy.
Butalbital: First trimester: Risk of major malformations (OR 1.4-2.0) including oral clefts; increased risk with prolonged use. Second and third trimesters: Avoid chronic use due to risk of neonatal withdrawal syndrome and hemorrhagic disease of newborn due to vitamin K deficiency. Acetaminophen: Considered low risk; no consistent evidence of teratogenicity. Caffeine: No increased risk of major malformations at moderate intake (<200 mg/day); high doses may be associated with growth restriction.
Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, and cardiovascular anomalies. Second and third trimesters: Potential for fetal dependence, withdrawal syndrome, and impaired brain development. Chronic use may cause fetal growth restriction and preterm birth.
Butalbital: Excreted into breast milk; M/P ratio unknown. Monitor infant for sedation, poor feeding, or withdrawal symptoms. Acetaminophen: Excreted in low amounts; M/P ratio approximately 1.0; considered compatible. Caffeine: Excreted in milk; M/P ratio 0.5-0.8; moderate intake likely safe; excessive use may cause irritability in infant.
Barbiturates are excreted into breast milk in low concentrations. M/P ratio is approximately 0.5-0.6. Chronic high-dose use may lead to infant sedation and difficulty feeding. Monitor infant for signs of drowsiness, lethargy, or poor suckling. Use caution, especially in neonates or preterm infants.
No specific dose adjustments for butalbital or acetaminophen based on pregnancy pharmacokinetics. However, avoid prolonged use or high doses. For caffeine, limit to <200 mg/day. Use lowest effective dose for shortest duration. Monitor for signs of butalbital accumulation in pregnancy due to increased volume of distribution; no formal recommendation for dose reduction.
Pregnancy induces hepatic microsomal enzymes, increasing barbiturate metabolism. Higher doses (increased by 30-50%) may be required to maintain therapeutic levels. Monitor serum drug levels if needed, especially in third trimester. Postpartum, reduce dose to prepregnancy levels to avoid toxicity.
Phrenilin is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; use with caution in patients with history of substance abuse or depression. Acetaminophen hepatotoxicity risk increases with doses >4g/day or in alcohol use disorder. Caffeine may exacerbate anxiety, insomnia, or tachyarrhythmias. Monitor for sedation and respiratory depression when used with other CNS depressants. Avoid abrupt discontinuation to prevent withdrawal symptoms.
Butabarbital is a short-acting barbiturate with a rapid onset; monitor for respiratory depression, especially when combined with other CNS depressants. Use with caution in hepatic impairment due to prolonged half-life. Tolerance and dependence develop with prolonged use; abrupt discontinuation may precipitate withdrawal seizures. Barbiturates induce CYP450 enzymes, potentially reducing efficacy of oral contraceptives, warfarin, and corticosteroids.
Take only as prescribed; do not exceed recommended dose to avoid liver damage or addiction.,Avoid alcohol while taking this medication due to increased risk of liver toxicity and sedation.,Do not drive or operate heavy machinery until you know how this medication affects you.,If you have a history of substance abuse, inform your doctor before taking this medication.,Common side effects include drowsiness, dizziness, and nausea. Report severe allergic reactions or signs of liver damage (yellowing skin/eyes, dark urine, abdominal pain).,Do not stop taking suddenly without consulting your doctor, as withdrawal symptoms may occur.,Keep out of reach of children; acetaminophen overdose can be fatal.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may cause severe sedation or respiratory depression.,Do not drive or operate heavy machinery until you know how this medication affects you.,Do not stop taking abruptly; withdrawal can cause anxiety, tremors, and seizures. Taper under medical supervision.,This medication may be habit-forming; store in a safe place to prevent misuse.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Inform your doctor of all medications you take, including herbal supplements and over-the-counter drugs.
No interactions on record
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHRENILIN vs BUTABARB, answered by our medical review team.
PHRENILIN is a Barbiturate/Analgesic Combination that works by PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.. BUTABARB is a Barbiturate that works by Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHRENILIN and BUTABARB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHRENILIN is: For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.. The standard adult dose of BUTABARB is: 15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHRENILIN and BUTABARB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHRENILIN is classified as Category C. Butalbital: First trimester: Risk of major malformations (OR 1.4-2.0) including oral clefts; increased risk with prolonged use. Second and third trimesters: Avoid chronic use due t. BUTABARB is classified as Category C. Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.